Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care and Induced Frailty
NCT ID: NCT02711709
Last Updated: 2025-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
53 participants
OBSERVATIONAL
2016-04-30
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PICS: Subtitle Cardiac Dysfunction in Older Sepsis Survivors
NCT02276417
Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS
NCT02276066
Impact of Frailty and ICU-AW on Post-ICU Fatigue Self-reported
NCT05984069
Impact of Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS) on the Respiratory Physiology in Patients With Prolonged Mechanical Ventilation
NCT07002710
Microbiome Dysfunction in Surgical Intensive Care Unit Survivors
NCT05357170
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In addition to the in-hospital clinical data collected from the parent study, pre and post-sepsis measurements of frailty, comorbidity and disability will be obtained via questionnaires and the electronic health records. Frailty, comorbidity and disability assessments will also be completed at the three, six, and 12 month follow up assessments.
Frailty measures A frailty index will be determined as a combination of factors.
An older adult is considered physically vulnerable when they experience:
1. muscle weakness
2. fatigue
3. low physical activity, and unintentional loss in body weight, which has been agreed upon by a consensus of experts.
Two additional non-intravenous contrasted CT scans will be obtained at 3 and 12 months as part of the study protocol to assess for interval change in SMI/sarcopenia.
Objective mobility and activity monitoring will be performed to supplement assessment of frailty and disability. Wearable monitors (similar in size and appearance to a "smart watch" have received significant attention because they offer minimal burden, objectivity, versatility and low cost for assessing activity and mobility patterns. The monitor is similar in shape and size to a standard wrist watch. Thus, it will have minimal burden to patients. Each monitor will be fitted on the wrist and worn for 24 hours a day, but can be quickly removed for medical procedures, patient care or hygiene needs. Patients will wear the monitor for their entire length of stay in the hospital. It will be removed at discharge. Post-discharge, patients will be sent a monitor to wear for up to 10 days at four different time points: 3 months, 6 months and 12 months post-discharge. If study subjects are hospitalized long enough that discharge is within 30 days of the 3 month follow up, the 1 month post discharge monitoring period will be deferred. Outcomes include steps per day, total movements per day, minutes being sedentary and minutes moving at various intensities (e.g. light, moderate and vigorous).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intra-abdominal sepsis
Frailty measurements. Modified Minnesota Leisure Time Activities. Computed tomography morphometrics. Mobility Monitors.
Frailty Measurements
A frailty index will be determined as a combination of factors.
An older adult is considered physically vulnerable when they experience:
1. muscle weakness
2. fatigue
3. low physical activity, and unintentional loss in body weight, which has been agreed upon by a consensus of experts.
This will be collected at baseline, 3, 6 and 12 months.
Modified Minnesota Leisure Time Activities
A questionnaire used to assess physical activity will be administered at baseline, 3, 6 and 12 months.
Computed tomography morphometrics
A CT scan will occur as standard of care while the patient is hospitalized. Two additional CT scans will occur at 3 and 12 months to assess for sarcopenia.
Mobility Monitors
Mobility monitors will be placed on the patients during the duration of their hospital stay. They will then where them at 3, 6 and 12 months for up to 10 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Frailty Measurements
A frailty index will be determined as a combination of factors.
An older adult is considered physically vulnerable when they experience:
1. muscle weakness
2. fatigue
3. low physical activity, and unintentional loss in body weight, which has been agreed upon by a consensus of experts.
This will be collected at baseline, 3, 6 and 12 months.
Modified Minnesota Leisure Time Activities
A questionnaire used to assess physical activity will be administered at baseline, 3, 6 and 12 months.
Computed tomography morphometrics
A CT scan will occur as standard of care while the patient is hospitalized. Two additional CT scans will occur at 3 and 12 months to assess for sarcopenia.
Mobility Monitors
Mobility monitors will be placed on the patients during the duration of their hospital stay. They will then where them at 3, 6 and 12 months for up to 10 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥18 years
* Diagnosis of sepsis, severe sepsis, or septic shock
* Entrance into the standard-of-care sepsis protocol
* Ability to obtain patient/legally authorized representative informed consent.
Exclusion Criteria
* Refractory shock (i.e., patients who die within 12 hours)
* Alternative or confounding diagnosis causing shock state (e.g., myocardial infarction or pulmonary embolus)
* Uncontrollable source of sepsis (e.g., irreversible disease state such as unresectable dead bowel),
* Patients deemed to be futile care or have advanced care directives limiting resuscitative efforts such as patient or patient's family who are not committed to aggressive management of the patient's condition. Expected lifespan of the patient is less than 3 months due to severe pre-existing comorbidities (ex. Recurrent, advanced or metastatic cancer).
* Severe Congestive Heart Failure (NY Heart Association Class IV)
* Child-Pugh Class C liver disease or pre-liver transplant.
* Known HIV infection with CD4 count\<200 cells/mm3,
* Organ transplant recipient on immunosuppressive agents
* Known pregnancy
* Inability to obtain informed consent
* Prisoners
* Institutionalized patients
* Chemotherapy or radiotherapy within 30 days prior to sepsis
* Spinal cord injuries resulting in permanent sensory and/or motor deficits.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Aging (NIA)
NIH
National Institutes of Health (NIH)
NIH
University of Florida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philip Efron, MD
Role: PRINCIPAL_INVESTIGATOR
University of Florida
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UF Health at Shands hospital
Gainesville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB201501027-N
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.